Patents by Inventor David N. Brems

David N. Brems has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE, ACTIVE, HUMAN OB PROTEIN COMPOSITIONS AND METHODS
    Publication number: 20020019352
    Abstract: The present invention relates to OB protein compositions and related methods. Provided herein are OB protein suspensions which are stable and active at physiologic pH. Such OB protein suspensions are useful for the treatment or modulation of weight adiposity level, diabetes, and other conditions.
    Type: Application
    Filed: April 14, 1998
    Publication date: February 14, 2002
    Inventors: DAVID N. BREMS, DONNA L. FRENCH, MARGARET A. SPEED
  • Somatotropin analogs
    Patent number: 5663305
    Abstract: The present invention provides analogs of animal somatotropins particularly with changes in the amino acids between residue 96 to 133 which are changed to reduce hydrophobicity or helical stability.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: September 2, 1997
    Assignee: The Upjohn Company
    Inventors: Sherwood Russ Lehrman, Henry A. Havel, Jody L. Tuls, Scott M. Plaisted, David N. Brems
  • Asp.sup.B1 insulin analogs
    Patent number: 5559094
    Abstract: Analogs of human insulin containing an aspartic acid at position 1 of the B chain (Asp.sup.B1), and optionally, having a gln modification at position 13 (Gln.sup.B13), display modified physico-chemical and pharmacokinetic properties which enable them to be long acting. These analogs are useful in the treatment of hyperglycemia because they are soluble and display an increased tendency to self-associate.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: September 24, 1996
    Assignee: Eli Lilly and Company
    Inventors: David N. Brems, Diane L. Bakaysa
  • Insulin analog formulations
    Patent number: 5474978
    Abstract: The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: December 12, 1995
    Assignee: Eli Lilly and Company
    Inventors: Diane L. Bakaysa, David N. Brems, Bruce H. Frank, Henry A. Havel, Allen H. Pekar